MediciNova (NASDAQ:MNOV) Now Covered by StockNews.com

by · The Cerbat Gem

StockNews.com began coverage on shares of MediciNova (NASDAQ:MNOV – Free Report) in a research report report published on Monday. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

MediciNova Price Performance

Shares of MediciNova stock opened at $1.81 on Monday. The business has a fifty day simple moving average of $1.67 and a two-hundred day simple moving average of $1.48. MediciNova has a 1 year low of $1.12 and a 1 year high of $2.16. The company has a market capitalization of $88.53 million, a price-to-earnings ratio of -10.62 and a beta of 0.75.

MediciNova (NASDAQ:MNOV – Get Free Report) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.01. As a group, equities analysts anticipate that MediciNova will post -0.23 earnings per share for the current fiscal year.

About MediciNova

(Get Free Report)

MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID.

Recommended Stories